Comparison
Magnesium L-Threonate vs NMN
Magnesium L-Threonate
MIT-developed magnesium that crosses the blood-brain barrier. Shown to enhance synaptic density and reduce 'brain age'.
NMN
Nicotinamide mononucleotide — NAD+ precursor. Studied for cellular aging and metabolic health.
| Field | Magnesium L-Threonate | NMN |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 1000–2000mg | 250–1000mg |
| Half-life | 6h | — |
| Onset | — | — |
| Evidence | EVIDENCEB | EVIDENCEB |
| Safety | ●●●●● | ●●●●● |
| Legal (US) | USOTC | USOTC |
| PubMed refs | 90 | 600 |
The comparison in plain English
Auto-generated from dataMagnesium L-Threonate and NMN are both in the neuroprotective category respectively. Magnesium L-Threonate MIT-developed magnesium that crosses the blood-brain barrier. NMN Nicotinamide mononucleotide — NAD+ precursor.
Bottom line
Magnesium L-Threonate (evidence B, safety 5/5) matches the evidence base of NMN (evidence B, safety 5/5). Magnesium L-Threonate has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Magnesium L-Threonate if
Magnesium L-Threonate is the better fit when your goal aligns with its mechanism (L-threonate is a sugar-acid carrier that uniquely enables magnesium to cross the blood-brain barrier in meaningful quantities — most oral magnesium forms (oxide, citrate, glycinate) raise serum magnesium but not central magnesium) and the dose range (1000–2000mg) suits your protocol. Half-life is 6h.
Choose NMN if
NMN is the better fit when your goal aligns with its mechanism (Direct precursor to NAD+ — one biosynthetic step closer than nicotinamide riboside, bypassing the NRK1/NRK2 enzymatic step) and the dose range (250–1000mg) suits your protocol. Half-life is —h.